Justin Spaulding, DO
Glaucoma Specialist · Medford, ORNPI 1013259167
Payments from drug & device makers
Across 133 payments — averaging $2327.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$241K
- Bausch & Lomb Americas Inc.$64K
- Nova Eye, Inc.$2K
- Alcon$1K
- AbbVie$257
- Sun Pharmaceutical Industries Inc.$228
- plus $1K from 17 others
What the payments were for
- Consulting fees$62,00090%
- Travel & lodging$2,8554%
- Food & beverage$3,9656%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 6 | $240,709 |
| Bausch & Lomb Americas Inc. | 27 | $63,509 |
| Nova Eye, Inc. | 6 | $2,471 |
| Alcon | 24 | $1,063 |
| AbbVie(2 entities) | 11 | $257 |
| Sun Pharmaceutical Industries Inc. | 12 | $228 |
| Glaukos Corporation | 4 | $181 |
| Novartis | 9 | $164 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $123 |
| Biotissue Holdings Inc. | 2 | $115 |
| Rxsight Inc | 2 | $110 |
| Harrow Eye, LLC | 3 | $106 |
| NEW World Medical,inc. | 7 | $104 |
| Dompe US, Inc. | 3 | $77 |
| Aerie Pharmaceuticals, Inc. | 3 | $65 |
| Apellis Pharmaceuticals, Inc. | 2 | $46 |
| Ellexiscience | 1 | $45 |
| Oyster Point Pharma, Inc. | 2 | $43 |
| Amgen(2 entities) | 2 | $42 |
| Tarsus Pharmaceuticals, Inc. | 2 | $38 |
| Ivantis, Inc | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Alimera Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$517
- Prokera$102
- AmnioGraft$102
- AmnioGuard$102
- LOTEMAX SM$100
How this compares
Too few glaucoma specialist providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 877 | $45,191 |
| MieboPerfluorohexyloctane/Pf | 45 | $33,922 |
| VyzultaLatanoprostene Bunod | 56 | $27,325 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 110 | $23,340 |
| RocklatanNetarsudil Mesylat/Latanoprost | 41 | $18,030 |
| LumiganBimatoprost | 25 | $16,720 |
| Latanoprost | 1,167 | $15,252 |
| RestasisCyclosporine | 24 | $14,311 |
| Travoprost | 89 | $10,695 |
| Ketorolac Tromethamine | 866 | $10,133 |
| Ofloxacin | 836 | $8,982 |
| Timolol Maleate | 730 | $7,756 |
| Methazolamide | 11 | $5,170 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 260 | $4,147 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $3,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $63,509 | $61,247101 claims |
| AbbVieLumigan, Restasis | $257 | $31,03149 claims |
| AlconSimbrinza | $1,063 | $23,340110 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $65 | $18,03041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Medford
- Helen KoenigsmanMedford$6K
- Brendan ButlerMedford$1K
- Christine PetersenMedford$1K
- Paul JorizzoMedford$151
- Steven MansbergerPortland$392K
- Charles WeberOregon City$6K
- Garrett ScottHillsboro$4K
- Hana TakusagawaEugene$3K
- Jonathan YoungTigard$1K
- Zoey StoumbosPortland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.